Transcriptomic phases of periodontitis lesions using the nonhuman primate model

Jeffrey L. Ebersole1,3*, Radhakrishnan Nagarajan2, Sreenatha Kirakodu3 & Octavio A. Gonzalez3,4

We used a nonhuman primate model of ligature-induced periodontitis to identify patterns of gingival transcriptomic after changes demarcating phases of periodontitis lesions (initiation, progression, resolution). A total of 18 adult *Macaca mulatta* (12–22 years) had ligatures placed (premolar, 1st molar teeth) in all 4 quadrants. Gingival tissue samples were obtained (baseline, 2 weeks, 1 and 3 months during periodontitis and at 5 months resolution). Gene expression was analyzed by microarray [Rhesus Gene 1.0 ST Array (Affymetrix)]. Compared to baseline, a large array of genes were significantly altered at initiation (n = 6049), early progression (n = 4893), and late progression (n = 5078) of disease, with the preponderance being up-regulated. Additionally, 1918 genes were altered in expression with disease resolution, skewed towards down-regulation. Assessment of the genes demonstrated specific profiles of epithelial, bone/connective tissue, apoptosis/autophagy, metabolism, regulatory, immune, and inflammatory responses that were related to health, stages of disease, and tissues with resolved lesions. Unique transcriptomic profiles occurred during the kinetics of the periodontitis lesion exacerbation and remission. We delineated phase specific gene expression profiles of the disease lesion. Detection of these gene products in gingival crevicular fluid samples from human disease may contribute to a better understanding of the biological dynamics of the disease to improve patient management.

Periodontal diseases are chronic dysregulated responses to dysbiotic microbiomes1–3. However, the literature is sparse regarding the earliest changes that occur in the local microbiome at sites that will transition from health to periodontal lesions. Furthermore, the disease is expressed temporally as exacerbations and remissions with the frequency and magnitude of the episodes explaining the variation in disease extent/severity across the population4,5. This episodic disease can occur at one or multiple sites sequentially or concomitantly, and appears to occur with greater incidence at sites that have already demonstrated a previous disease process6–8.

A challenge in the field is that sampling of humans for the comprehensive biology of the disease process remains somewhat problematic for detailing the dynamics of an episodic disease. The experimental designs are generally limited to a point-in-time with clinical definition of health or disease at that point. While human disease can be clinically monitored over time at multiple sites per tooth and across the dentition, the inability to sample site-specific tissues on multiple occasions, makes the assessment of the biology of the tissues representing differences in phases of initiation, progression, stabilization, or resolution of the disease lesion at a particular site challenging. Additionally, while investigations of periodontitis in rodents and rabbits6,10 clearly can provide useful information regarding the underlying biology of local and systemic host responses, the autochthonous complex microbiomes are completely different in these species versus humans, and the major oral pathogens in human disease have no tropism for colonizing rodents and rabbits11–13. Thus, we and others have employed a nonhuman primate model of periodontal disease over the last nearly 40 years. It has been shown that the microbiology, immunology, and clinical expression of periodontitis are quite similar in humans and nonhuman primates, including naturally-occurring disease that increases with aging14-16. We have also recently reported a familial relationship of periodontitis susceptibility and resistance in multigenerational matrilines of *Macaca mulatta*14 consistent with some heritability/genetic contribution to the disease, as has been described in humans17–19.
Thus, this report describes longitudinal studies of biological processes of periodontitis using a nonhuman primate model of ligature-induced disease. Gene expression profiles were determined in gingival tissues with health and during initiation, progression, and resolution of periodontitis, reflecting the episodic nature of the disease in humans. The hypothesis tested was that there would be unique gene expression profiles that discriminate phases of periodontitis. The findings would shed some light into the temporal nature of changes in biological factors/pathways through the disease process. This would provide the potential for identifying targeted biomolecules that could be used to better characterize disease sites in humans, and identify differences in the biological characteristics of healthy (never diseased) sites from previously diseased sites that have been successfully treated, as potential biomarkers of future risk for disease.

**Results**

**Dynamics of periodontitis lesions.** Figure 1 provides a schematic model of periodontitis as suggested from human studies of exacerbation and remission of clinical features of disease. It is well recognized that periodontitis is generally not expressed until about the 3rd–4th decade of life, even though the host response system and oral microbiome are interacting during a 30+ year time period prior to disease. Existing data support that many or most of the bacteria generally associated with periodontitis are also present in younger individuals, who often demonstrate substantial gingival inflammation, but do not appear to transition to destructive disease. Additionally, numerous reports have suggested a genetic contribution to disease related to gene polymorphisms that would exist from the beginning of life in at-risk individuals. Thus, the “risk microbiome” and “risk genetic predisposition” occur for decades prior to clinical disease expression. At some point within an individual at one or more sites a disease process is initiated. Based upon the biology of how a host reacts to a bacterial challenge, this initial insult would likely last for days or weeks, either resolving rapidly or transitioning to progressing disease. It is unknown regarding the temporal linkage of the biological changes with detectable clinical disease, but it would be predicted that this interaction occurs with disease progression over weeks to months based upon rodent and nonhuman primate experimental data. While once clinical tissue destruction has occurred, it is irreversible, human studies would support that the disease can and does resolve biologically, limiting the extent of destruction. With a particular disease lesion, this now stabilized site may exist for weeks or even years; however, human studies support that the greatest predictor of formation of a periodontal lesion is past disease at the same site. Nevertheless, there is minimal guidance regarding the biology of resolved sites relative to future disease exacerbations. Thus, we implemented a study to examine this temporal nature of the disease process in nonhuman primates, focusing on gingival gene expression profiles to identify unique biologic processes occurring at the different stages of disease.

Figure 2 summarizes the clinical presentation of ligated teeth for bleeding on probing and probing pocket depth. Consistent with previous studies, inflammation and tissue destructive changes occurred rather rapidly following initiation of the challenge (i.e. 0.5 months), and continued to progress over 1–3 months. Removal of
the ligatures after sampling at 3 months resulted in a general clinical resolution of these disease features that approximated the baseline health values.

Gene expression profiles in periodontitis lesions. A detailed examination (Table 1) showed a substantial number of genes with significant differences from baseline samples. These included genes that were both up- and down-regulated at ≥ 1.5-fold with disease initiation and progression. Interestingly, while there was a large number of genes that were significantly different between disease resolution and baseline, only about 400 demonstrated this fold-level of differential expression.

Since a goal was to identify genes that were uniquely expressed at each time point, the plots in Fig. 3 provide the features of expression for subsets of the genes for baseline expression compared to the other time points. As shown, 358, 330, 271, and 80 genes at 0.5, 1, 3 and 5 months, respectively that fulfilled the threshold of ≥ 1.5 difference between baseline and any other time point. Of interest was that during disease these genes were up-regulated, while at resolution the distinctive genes were expressed at a lower-level than baseline. Figure 3c depicts a similar analysis of gene expression during disease initiation, progression and resolution compared to all other phases. This differential expression showed a limited number of genes (n = 20) and (n = 24) that were distinct at 0.5 and 1 month, respectively. At 3 months (late progression), 68 genes showed increased or decreased expression by > twofold. As noted with the baseline comparison the primary effects on gene expression with resolution was a profile of significantly (p < 0.05) decreased expression of genes (n = 18) compared to the other time points.

Functional characteristics of gene expression of periodontitis lesions. The next step in the process was to identify those genes/pathways that provided unique signatures for baseline healthy tissues, tissues

| Sample (mo.) | Stage          | P-value < 0.01 | Gene expression changes (%) |
|--------------|----------------|----------------|-----------------------------|
|              |                | Total#         | UP (Fold ≥ 1.5) | DOWN (Fold ≥ 1.5) |
| 0.5          | Initiation     | 6049           | 943             | 472              |
| 1            | Early progression | 4893         | 692             | 471              |
| 3            | Late progression | 5078          | 542             | 372              |
| 5            | Resolution     | 1918           | 176             | 221              |

Figure 2. Clinical features of inflammation (bleeding on probing, BOP) and destructive disease (probing pocket depth, PPD) in ligated sites of the nonhuman primates. Ligatures were removed after clinical measures at 3 months, with 5 month samples representing clinical resolution. The points denote the mean values from 18 animals and the vertical brackets enclose 1 SD.

Table 1. Distribution of altered gene expression in gingival tissues during ligature-induced periodontitis and at disease resolution compared to baseline healthy tissues.
Figure 3. (A) Patterns of gene expression with disease and resolution compared to baseline/health. (B) Patterns of gene expression in baseline/health versus all other time points. (C) Patterns of gene expression with disease and resolution compared all other time points in the model. Numbers in parentheses denote number of genes within the particular patterns, and whether the patterns denoted up (↑) or down-regulation (↓) of the gene expression.
Figure 3. (continued)

from sites with initiation and progression of disease, and tissue samples from clinically resolved lesions. Figure 4 summarizes the functional categories of the genes that were increased or decreased by > twofold at each of the phases compared to baseline healthy tissues. Numerous genes related to epithelial cell biology were affected as early as 2 weeks (Initiation) and remained different from health throughout lesion progression and even in resolution tissues. Inflammation genes were overly represented at disease initiation; decreasing in number with disease progression. Additionally, cellular metabolic and regulatory genes were affected rapidly at disease initiation and early progression and decreased in representation in late progression and resolution. Finally, adaptive immune genes were highly represented in early and late disease progression, with many remaining altered even in resolution samples. Table 2 provides a summary of the gene expression profile functions that were phase-related across health, disease and resolution samples. In healthy tissues, epithelial cell, metabolic, and regulatory genes generally were elevated and down-regulated with disease. In contrast, genes related to adaptive immune responses were expressed at low levels in healthy tissues and increased significantly in prevalence with disease. With disease initiation, the number of inflammatory genes were substantially increased as were changes in additional genes related to epithelial cell functions and integrity of the epithelium. Early progression showed a more limited number of genes that were differentially expressed (> twofold) compared to all other time points, primarily for epithelial cell genes (decreased) and adaptive immune genes (increased). A distinctive gene profile was observed during late progression, with 96% of the phase specific genes associated with adaptive immune responses. Finally, in resolution samples, a low number of unique differentially expressed genes was observed with expression of primarily inflammation-associated genes remaining elevated.

A listing of genes that specifically hallmark healthy gingival tissues from the stages of disease or resolved lesions is provided in Table 3. Of these 43 genes, those related to epithelial cells, were generally expressed in
significantly elevated levels in healthy tissues and decreased with onset of disease. In contrast, cellular metabolism, regulatory, and inflammation/immune genes were increased with disease onset and progression. Table 3 also provides a similar summary identification of 45 genes that hallmark disease initiation/early progression of the lesion. These genes were generally up-regulated during these stages of disease and were represented by a broad mix of functions, generally significantly increased over baseline healthy levels. Examination of unique phase specific gene expression profiles during late progression of disease identified 45 altered transcript signals (Table 3). These were skewed towards genes related in inflammation and immune responses. As with gene expression at initiation/early progression, these identified genes were increased compared to baseline samples. However, the most prominent markers comprising > 50% of the up-regulated genes were associated with immunoglobulin formation and antibody recombination processes of adaptive immune responses. Finally, we identified gene differences (n = 33) in baseline healthy sites versus sites that appeared clinically healthy post-resolution of a disease process (Table 3). Of note was that a number of these genes were decreased from health with disease and continued at a lower level of expression in the resolution samples, albeit, at levels improved over the disease samples (e.g. keratins, LIPM). MUC4 was unique in that it was increased with disease, but increased to even greater levels once the disease had resolved. In contrast, EGR1 was decreased with disease from health and was down-regulated even more in resolution samples. Additionally, some genes, e.g. CD36, PTGS2 genes were decreased only in resolved disease tissues versus health or disease. No differences were noted in these gene expression profiles based on sex of the animals. While not included in the table, an observation was that of the array of Ig genes of adaptive immunity that were significantly elevated in late progression, remained elevated in resolution compared to healthy tissue samples.

Discrimination of gingival tissues in health and disease. We then evaluated the capacity of these subsets of differentially expressed genes to discriminate the various stages of health and disease in the gingival samples. A principal components analysis (Fig. 5) summarizes the results. These Principal Components accounted for 62% of the variation in the samples derived from the various time points. As noted the baseline healthy samples and disease initiation (0.5 months) samples demonstrated the greatest discrimination. Also, the distribution of resolution samples suggests a subset that overlapped with healthy patterns, and a second subset appeared more similar to the expression profiles for late progression (3 months). Finally, the early progression samples showed some separation from the other disease points, although the individual variation and overlap with both initiation and/or late progression, supported the limited number of unique gene patterns for the 1 month time point.

Classification of phases of periodontitis lesions using gene expression profiles. Finally, using a set of 67 genes, based upon differential expression at one or more of the timepoints, we created a flow chart to determine expression levels of each of these genes related to discriminating the phase of disease (Supplementary Fig. S1). From this measure, we determined threshold values for the ratios that were distinctive for the healthy and disease phase samples. We then determined for each sample, the number of expression values for individual gingival samples that fell above or below the threshold. This resulted in 4 different gene clusters (1-IV) represented by 20, 12, 16 and 18 genes respectively (Table 4). Additionally, subgrouping the Cluster I genes into IA and IB with a different threshold (Table 4) was effective in differentiating the baseline healthy samples to those tissues with clinically resolved lesions. Figure 6 provides a summary of the 18 specimens collected at each of the 5 time points. As noted Clusters I-IV identified health from disease with 15/18 health and only 3/18 were misclassified. Cluster II-IV gene response profiles accurately categorized 15/18 samples at disease initiation (2 weeks) and 17/18 samples at the time of late disease progression (3 months). Of interest was using these 3 clusters of responses, the early progressing lesions demonstrated a very mixed pattern of responses with 2 samples classified with health, 4 samples classified with initiation, 9 samples classified with early progression, and 3 classified with late progression specimens. The results suggest that the early progression of the lesion appears to vary biologically across the individual animals in response to the ligature challenge. Figure 6 also demonstrates the ability of the response profile of genes in Cluster IA and IB to classify what appears to be a different biology of the baseline healthy samples to those from teeth that had lesions that had clinically resolved. Using the adjusted thresholds, 13/18 healthy and 11/18 resolution samples were accurately classified.

Discussion

Critical features of the underlying biological processes that occur during the transition from periodontal health to disease remain elusive. It is clear that accompanying the clinical changes that hallmark this site specific mucosal disease, numerous biomarkers of inflammation and altered innate and adaptive immune response parameters can be detected in the subgingival sulcus via gingival crevicular fluid and even in whole saliva reflecting these local changes. While an array of reports using rodent models of disease have attempted to document the various host response components that contribute to the clinical changes, these models are limited by a lack of any similarity to the oral microbiome in human disease. Moreover, they generally use a biased host response assessment focusing on individual or a finite array of factors of interest. Papapanou and colleagues have reported a range of studies of human gingival tissue transcriptomes comparing chronic to aggressive disease, and attempting to identify crucial pathways and transcription factors that associate with existing disease. An observation from these data was the extensive heterogeneity in expression of genes in diseased tissues generally attributed to individual variation in host response genetics and the individual's oral microbiome. However, this report describes an additional alternative for the variation in the human transcriptome profiles, that is, the human samples are obtained at a point-in-time and classified by clinical measures that could have occurred weeks/months previously, could reflect ongoing progression, or could be a disease stable site only presenting a history
of a disease process. Thus, we employed a monkey model of ligature-induced disease by which we can directly identify initiation, progression, and resolution of periodontal lesions that would be difficult to accomplish in the human disease model.

This experimental model enabled us to identify transcriptomes in the gingival tissues derived from different phases of the disease process. The goal of detailing the transcriptome would be to document arrays of genes with elevated or depressed expression that discriminated healthy tissues, as well as initiation and progression of

---

**Table 2.** Identification of altered gene expression in gingival tissues, with functional patterns unique to each phase of health, disease and resolution by comparison to gene expression profiles in all other phases of lesion formation and resolution. Value denote number of genes represented in each category. Fxn denotes functional categorization of genes: *Epi* epithelium, *Conn* connective tissue, *Bone*, *Meta* metabolic, *Regul* regulatory, *Inflam—inflammation, Inn* innate immune, *Adap* adaptive immune, *Auto* autophagy, *Apop* apoptosis, *Pseudo—pseudogene.*

| Phase               | Total | Functional categorization |
|---------------------|-------|--------------------------|
|                     |       | Epi | Meta | Regul | Inflam | Imm | Adap | Conn | Vasc | Auto | Apop | Bone | Pseudo |
| Health/BL           | 163   | 45  | 21   | 13    | 10    | 13  | 49   | 6    | 2    | 2    | 0    | 0    | 1      |
| Initiation/2 wks    | 70    | 13  | 7    | 8     | 23    | 1   | 3    | 7    | 5    | 0    | 0    | 0    | 0      |
| Early progression/1 mo | 20   | 10  | 0    | 1     | 1     | 0   | 7    | 1    | 0    | 0    | 0    | 0    | 0      |
| Late progression/3 mo | 50   | 0   | 0    | 1     | 1     | 0   | 48   | 0    | 0    | 0    | 0    | 0    | 0      |
| Resolution/5 mo     | 17    | 1   | 1    | 2     | 10    | 0   | 2    | 1    | 0    | 0    | 0    | 0    | 0      |

**Figure 4.** Depiction of the array of genes in various functional categories that differed by ≥ twofold at health versus other sampling points. Pie charts denote the proportions of each functional category of genes that comprised the overall number of genes (in parentheses) that were differentially expressed.
| Gene ID  | FXN                  | Ontology                                      |
|----------|----------------------|-----------------------------------------------|
| Health versus disease                                      |
| ANAX3    | Conn                 | Annexin A3                                    |
| DRAM1    | Conn                 | DNA damage regulated autophagy modulator 1    |
| MMP1     | Conn                 | Matrix metalloproteinase 1                    |
| PXDN     | Conn                 | Peroxidase                                    |
| SERPINE2 | Conn                 | Serpin family E member 2                      |
| TFPF     | Conn                 | Tissue factor pathway inhibitor               |
| ALOXE3   | Epi                  | Arachidonate lipoxygenase 3                   |
| ALOX12B  | Epi                  | Arachidonate 12-lipoxygenase, 12R type        |
| CDSN     | Epi                  | Corneodesmosin                                |
| CRNN     | Epi                  | Cornulin                                      |
| DSC1     | Epi                  | Desmocollin 1                                 |
| KLK5     | Epi                  | Kallikrein related peptidase 5                |
| KRT1     | Epi                  | Keratin 1                                     |
| KRT2B    | Epi                  | Keratin, type II cytoskeletal 2 oral-like     |
| LCE3C    | Epi                  | Late cornified envelope 3C                    |
| NID1     | Epi                  | Nidogen 1                                     |
| ODAM     | Epi                  | Odontogenic, ameloblast associated            |
| PRR9     | Epi                  | Proline rich 9                                |
| RPTN     | Epi                  | Repetin                                       |
| SERPINB13| Epi                  | Serpin family B member 13                     |
| SPINK9   | Epi                  | Serine peptidase Inhibitor, Kazal Type 9      |
| BPIL2/BPILFC| Imm                | Bactericidal/permeability increasing protein-like 2 |
| SIRPB1   | Imm                  | Signal regulatory protein beta 1             |
| SLAMP6   | Imm                  | SLAM family member 6                           |
| WFDC12   | Imm                  | WAP four-disulfide core domain 12             |
| CD177    | Inflam               | CD177 molecule                                |
| CSF3R    | Inflam               | Colony stimulating factor 3 receptor (granulocyte) |
| CXCL8    | Inflam               | Interleukin 8                                 |
| CXCL6    | Inflam               | Chemokine (C-X-C motif) ligand 6              |
| GSDMA    | Inflam               | Gasdermin A                                  |
| HPGD     | Inflam               | 15-Hydroxyprostaglandin dehydrogenase         |
| IL36B/IL1F8| Inflam           | Interleukin 36 beta                           |
| SERPINB5 | Inflam               | Serpin family B member 5                      |
| TNFRSF19 | Inflam               | TNF receptor superfamily member 19            |
| AADAC    | Metab                | Arylacetamide deacetylase                     |
| AKR1C3   | Metab                | Aldo-κeto reductase family 1 member C3        |
| ALAS2    | Metab                | 5′-aminolevulinate synthase 2                 |
| ARSF     | Metab                | Arylsulatase F                                |
| ESYT3    | Metab                | Extended Synaptotagmin 3                      |
| SERPINA3 | Metab                | Serpin family A member 3                      |
| TDH      | Metab                | L-threonine dehydrogenase (pseudogene)        |
| PAM178B  | Regul                | Family with sequence similarity 178 member B  |
| BN1U6-1  | Regul                | U6 spliceosome                                |
| Initiation/early progression                               |
| BLK       | Adap                 | BLK proto-oncogene, Src family tyrosine kinase |
| IGKV1-ACY*02| Adap          | Immunoglobulin kappa variable 1 ACY*02        |
| IGKV1514*01| Adap          | Immunoglobulin kappa variable 1514*01        |
| IGKV3-ACF*02| Adap          | Immunoglobulin kappa variable 3 ACF*02        |
| IGLV259*01| Adap          | Immunoglobulin lambda variable 2S-9*01        |
| MZB1     | Adap                 | Marginal zone B and B1 cell specific protein  |
| MUC4     | Auto                 | Mucin 4, cell surface associated              |
| NAIP     | Auto                 | NLR family apoptotic inhibitory protein       |
| RUBCNL   | Auto                 | Rubicon like autophagy enhancer               |
| ACTA2    | Epi                  | Actin alpha 2, smooth muscle                  |
| ADAM12   | Epi                  | ADAM metallopeptidase domain 12               |

Continued
| Gene ID | FXN | Ontology |
|---------|-----|----------|
| KRT8    | Epi | Keratin 8 |
| KRT15   | Epi | Keratin 15 |
| NID2    | Epi | Nidogen 2 (osteoidogen) |
| PLIN2/ADFP | Epi | Perilipin 2 |
| COL4A2  | Conn | Collagen type IV alpha 2 |
| ESM1    | Conn | Endothelial cell-specific molecule 1 |
| HAS2    | Conn | Hyaluronan synthase 2 |
| PLAG1   | Conn | Plasminogen activator, urokinase |
| PLAT    | Conn | Plasminogen activator, tissue type |
| ADAMTS9 | Metab | ADAM metallopeptidase with thrombospondin type 1 motif 9 |
| CTSL    | Metab | Cathepsin L |
| CYP4F3  | Metab | Cytochrome P450 family 4 subfamily F member 3 |
| NOX4    | Metab | NADPH oxidase 4 |
| MTHPS   | Metab | Methylenetetrahydrofolate synthetase |
| MSMO1   | Metab | Methylsterol monoxygenase 1 |
| SLC11A1 | Metab | Solute carrier family 11 member 1 |
| SULF1   | Metab | Sulfatase 1 |
| TGM2    | Metab | Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) |
| IL1B    | Inflam | Interleukin 1 beta |
| MIR223  | Inflam | microrna 223 |
| NLRP12  | Inflam | NLR family pyrin domain containing 12 |
| SELL    | Inflam | Selectin L |
| TLR2    | Imm | TOLL like receptor 2 |
| TLR4    | Imm | Toll-like receptor 4 |
| IL33    | Imm | Interleukin 33 |
| LILRA2  | Imm | Leukocyte immunoglobulin like receptor A2 |
| PLAC8   | Imm | Placenta associated 8 |
| CCDC9   | Regul | Coiled-coil domain containing 9 |
| GLI3    | Regul | GLI family zinc finger 3 |
| HGF     | Regul | Hepatocyte growth factor |
| RGS18   | Regul | Regulator of G protein signaling 18 |
| SFRP4   | Regul | Secreted frizzled related protein 4 |
| OR6K6   | Sig | Olfactory receptor family 6 subfamily K member 6 |
| RTP3    | Sig | Receptor transporter protein 3 |
| VWF     | UA | Von Willebrand factor |

**Late progression**

| Gene ID | FXN | Ontology |
|---------|-----|----------|
| IGHG3*02 | Adap | Immunoglobulin heavy constant gamma 3 |
| IGHM    | Adap | Immunoglobulin heavy constant mu |
| IGHV3-49 | Adap | Immunoglobulin heavy variable 3–49 |
| IGHV3-72 | Adap | Immunoglobulin heavy variable 3–72 |
| IGHV3-73 | Adap | Immunoglobulin heavy variable 3–73 |
| IGHV3-AGQ*02 | Adap | Immunoglobulin heavy variable 3 AGQ*02 |
| IGF     | Adap | joining chain of multimeric IgA and IgM |
| IGKV1-9  | Adap | Immunoglobulin kappa variable 1–9 |
| IGKV1-ABV*02 | Adap | Immunoglobulin kappa variable 1 ABV*02 |
| IGKV1-ACY*02 | Adap | Immunoglobulin kappa variable 1 ACY*02 |
| IGKV1z   | Adap | Immunoglobulin kappa variable 1z |
| IGKV2-ABW*04 | Adap | Immunoglobulin kappa variable 2 ABW*04 |
| IGKV23S19*01 | Adap | Immunoglobulin kappa variable 2S19*01 |
| IGKV3-ADU*02 | Adap | Immunoglobulin kappa variable 3 ADU*02 |
| IGKV4-1  | Adap | Immunoglobulin kappa variable 4–1 |
| IGKV1-ABB*02 | Adap | Immunoglobulin lambda variable 1 ABB*02 |
| IGKV1-ACV*02 | Adap | Immunoglobulin lambda variable 1 ACV*02 |
| IGKV2a   | Adap | Immunoglobulin lambda variable 2a |
| IGKV2-ABU*02 | Adap | Immunoglobulin lambda variable 2 ABU*02 |
| IGKV3-AAV*04 | Adap | Immunoglobulin lambda variable 3 AAV*04 |

Continued
| Gene ID     | FXN     | Ontology                                      |
|------------|---------|----------------------------------------------|
| IGLV5-AAX‘02 | Adap    | Immunoglobulin lambda variable 5 AAX‘02      |
| IGLV7-46   | Adap    | Immunoglobulin lambda variable 7–46         |
| IGLV8-61   | Adap    | Immunoglobulin lambda variable 8–61         |
| KLHL6      | Adap    | Kelch like family member 6                   |
| COL4A2     | Conn    | Collagen type IV alpha 2                     |
| KRT24      | Epi     | Keratin, type I cytoskeletal-like            |
| THBS1      | Epi     | Thrombospondin 1                             |
| BANK1      | Imm     | C cell scaffold protein with ankyrin repeats 1 |
| FPR3       | Imm     | Formyl peptide receptor 3                   |
| GREM1      | Imm     | Gremlin 1, DAN gamly BMP antagonist          |
| LST1       | Imm     | Leukocyte specific transcript 1              |
| SERPINB5   | Imm     | Serpin family B member 5                    |
| TEK        | Imm     | TEK receptor tyrosine kinase                 |
| CD36       | Inflam  | CD36 molecule (thrombospondin receptor)      |
| CXCRI      | Inflam  | Chemokine (C-X-C motif) receptor 1           |
| PTGS2      | Inflam  | Prostaglandin-endoperoxide synthase 2        |
| TREM1      | Inflam  | Triggering receptor expressed on myeloid cells 1 |
| BCAT1      | Metab   | Branched chain amino acid transaminase 1     |
| DYSF       | Metab   | Dysferlin                                    |
| KYNU       | Metab   | Kynureninase-like                            |
| SLC2A14    | Metab   | Solute carrier family 2 member 14            |
| SLC15A1    | Metab   | Solute carrier family 15 member 2            |
| SNORD105   | Regul   | Small nuclear RNA, C/D box 116–17            |
| TENT5C     | Regul   | Terminal nucleotidytransferase 5C            |
| ZNF337     | Regul   | Zinc finger protein 337                     |
| UTS2B      | Sig     | Urotensin 2B                                |

**Gene ID**

| Gene ID     | FXN     | Ontology                                      |
|------------|---------|----------------------------------------------|
| IGLV2S9‘01 | Adap    | Immunoglobulin lambda variable 2S-9‘01       |
| IGH3-ADR‘02| Adap    | Immunoglobulin heavy variable 3 ADR‘02      |
| DRAM1      | Conn    | DNA damage regulated autophagy modulator 1   |
| ESM1       | Conn    | Endothelial cell-specific molecule 1         |
| TFPI       | Conn    | Tissue factor pathway inhibitor              |
| MMP1       | Conn    | Matrix metalloproteinase 1                   |
| PXDN       | Conn    | Peroxidasin                                  |
| KLK5       | Epi     | Kallikrein related peptidase 5               |
| KRT1       | Epi     | Keratin 1                                   |
| KRT10      | Epi     | Keratin 10                                  |
| KRT75      | Epi     | Keratin 75                                  |
| LCE3C      | Epi     | Late cornified envelope 3C                   |
| LIPM       | Epi     | Lipase Family Member M                      |
| ALOX12B    | Epi     | Arachidonate 12-lipoxygenase, 12R type       |
| KRT2B      | Epi     | Keratin, type II cytoskeletal 2 oral-like    |
| NID1       | Epi     | Nidogen 1                                    |
| ODAM       | Epi     | Odontogenic, ameloblast associated           |
| PRR9       | Epi     | Proline rich 9                               |
| SPINK9     | Epi     | Serine peptidase Inhibitor, kazal type 9     |
| CRNN       | Epi     | Cornulin                                     |
| DSC2       | Epi     | Desmocollin 1                                |
| SIRPB1     | Imm     | Signal regulatory protein beta 1             |
| SLAMF6     | Imm     | SLAM family member 6                         |
| WDFC12     | Imm     | WAP four-disulfide core domain 12            |
| CSF3R      | Inflam  | Colony stimulating factor 3 receptor (granulocyte) |
| CXCL8      | Inflam  | Interleukin 8                                |
| CXCL6      | Inflam  | Chemokine (C-X-C motif) ligand 6             |
| HPGD       | Inflam  | 15-Hydroxyprostaglandin dehydrogenase        |
| PTGS2      | Inflam  | Prostaglandin-endoperoxide synthase 2        |

Continued
disease, and finally were uniquely expressed with disease resolution. As was expected there was a large number of genes that changed in transition from health to disease, including 900–1400 that were significantly different and either increased or decreased with disease. Additionally, there was a large number of genes that were significantly different between healthy and resolved tissues, albeit a rather limited number with substantial fold-differences.

A global transcriptomic analysis revealed a panel of genes that were specifically elevated in healthy tissues, as well as portfolios of genes that showed unique patterns at 0.5 months (initiation), 1 month (early progression), and 3 months (late progression) compared to the other time points. We also noted a panel of genes with levels elevated in resolved lesions compared to baseline or disease phases. In order to drill down more deeply within the transcriptome to identify the genes of interest, we increased the stringency for inclusion in developing these phase specific panels. This approach provided a subset of about 200 + genes that showed differential expression at the phases of disease and healthy tissues. Interestingly, at this increased level of stringency we found 53 genes in resolved tissues that differed from baseline with 59% showing decreased expression. A second step was to explore features of the panels that discriminated disease initiation from other disease phases or resolution. The results demonstrated few genes that differed uniquely between initiation and early progression. Thus, while the clinical parameters increased significantly from 2 weeks (0.5 months) to 1 month, it appears that changes in gene expression occur rapidly and are maintained during this early progression phase of disease. In contrast,

| Gene ID  | FXN   | Ontology  |
|----------|-------|-----------|
| AKR1C3   | Metab | Aldo–Keto Reductase Family 1 Member C3 |
| EGR1     | Regul | Early growth response 1 |
| FOS      | Regul | Fox proto-oncogene, AP-1 transcription factor subunit |
| RNU6-1   | Regul | U6 spliceosome |

Table 3. Identification of altered gene expression in gingival tissues: comparing healthy versus diseased gingival tissues (n = 43; in all cases levels of gene expression were elevated in healthy tissues); during initiation/early progression of disease (n = 45); during late progression of disease (n = 46); and comparing baseline healthy tissues to clinically resolved lesions (n = 33). The Adap genes are the human ID designation related to antibody nucleotide sequences of the macaque probes. Numerous of the matching macaque sequence Ig gene IDs are delineated in Thulliere et al.75. Fxn denotes functional categorization of genes: Adap adaptive immune response, Conn connective tissue/bone, Epi epithelium, Imm immune response, Inflam inflammation, Metab metabolic, Regul regulatory, Auto autophagy/apoptosis, Sig cellular signaling, UA unassigned to any of these functions.

Figure 5. Principal components analysis of the 89 gingival tissue samples using the profile of discriminatory genes identified as disease phase-related. Each point denotes the profile of gene expression for an individual gingival tissue sample collected at baseline (healthy), 0.5 months (initiation), 1 month (early progression), 3 months (late progression), and 5 months (resolution).
we identified 104 genes that identified tissues at late disease progression versus levels in tissue samples during disease initiation with 58% of the expression levels greater in late progression. This suggested the likelihood of some specific gene profiles whose function may contribute to the continued progression of the disease lesions. Finally, a number of genes (n = 55) were decreased in resolved tissues compared to expression during any phase of disease. Most of these represented gene expression levels that were returning back towards baseline levels consistent with the improved clinical parameters.

These findings documented the existence of genes that demonstrated significant differences across the biologic phases of the disease process and enabled the creation of profiles of “phase-specific” genes. The genes elevated in health, but never in diseased tissues were over-represented for biologic pathways of epithelial cell functions, metabolism, and inflammation (Table 2). As these gene expression variations represent early disease changes in this human-like disease model, potentially a subset of these gene products could be targeted as early biomarkers of disease in humans, potentially enabling earlier identification and intervention to minimize tissue damage.

The data also explored the determination if a pattern of genes was also relatively specific for what would be considered “early progression” (1 month) in this model related to clear increases in the trajectory of clinical parameters of BOP and PPD. Interestingly, a rather broad variation in expression of the various clusters of genes was noted during early progression. In the nonhuman primate model, extensive studies of clinical measures have demonstrated a general expression of periodontal disease within 1 month post-ligation in nearly all animals although the rate differs for individual animals42–44. Also, a portion of the animals demonstrate clinical measures that show minimal increases between 1 and 3 months (early responders), while a subset of the animals clearly demonstrate a continued progression of disease, reaching maximum PPD at the 3 month time point, which we defined as “late progression”. As such, the gene analysis prediction grouped selected animals at early progression as either initiation, early or late progression, suggesting an extent of biologic variation in the population during the early transition to progressing destructive disease. This type of temporal variability is likely also reflected within the human population based upon clinical measures of gingivitis and progressing periodontitis, albeit little

### Table 4. Gene clusters used to categorize the gingival samples. The threshold cutoff ratio determined as Tc for the normalized signal.

| Gene cluster | I   | II  | III | IV  | V   | Tc  | Tc  | Tc  | Tc  |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| TNFRSF19     | >150| ADAM12 | >1200 | DYSF | >400 | CD8N | >1300 |     |     |
| ANAX3        | >200| PLAT  | >150 | KYNU | >80  | CEACAM8 | >600 |     |     |
| SERPINE2     | >400| MIR233 | >400 | SLC2A14 | >500 | LCE3C | >200 |     |     |
| CD177        | >425| NOX4  | >500 | CXCRI | <500 | NID2  | >1500 |     |     |
| CSF3R        | <350| BLK   | >150 | SERPINB5 | >500 | THBS1 |     |     |     |
| ALOX12B      | >300| KRT1  | >75  | KRT24 | >250 | COL15A1 | >100 |     |     |
| KRT2B        | >100| MUC4  | >800 | MZB1  | >175 | COL4A1 | >500 |     |     |
| NID1         | >50 | TLR4  | >350 | EGR1  | >65  | SERPINE1 | >400 |     |     |
| MMP1         | >300| HASA2 | >225 | CD36  | >200 | TGM2  | >1100 |     |     |
| PXDN         | <125| TEK   | >200 | PTGS2 | >400 | HGF   | <350 |     |     |
| CRNN         | >300| CTSL  | >350 | LST1  | >400 | TREM1 | <750 |     |     |
| DSC1         | >300| RUBCNL | >150 | COL4A2 | >300 | SELL  |     |     |     |
| DRAM1        | >60 | GREM1 | >450 | CLDN10| >200 |       |     |     |     |
| ESM1         | <175| EPR3  | >350 | SFRP4 | >325 |       |     |     |     |
| TFFP         | <1000| MZB1 | >1000 | SNORD116 | >150 |       |     |     |     |
| SIRPB1       | <1300| CTP4F3 | >225 | TENT5C | >1700 |       |     |     |     |
| HPGD         | >350|       |     |       |     | BANK1 | >150 |     |     |
| CXCL8        | <200|       |     |       |     | RCAT1 | >75 |     |     |
| CXCL6        | >100|       |     |       |     |       |     |     |     |
| SLAMF6       | >600|       |     |       |     |       |     |     |     |
| IA          | Tc  | IB   | Tc  |     |     |     |     |     |     |
| CSF3R        | <350| CRNN  | <300 |     |     |     |     |     |     |
| ALOX12B      | >350| DSC1  | <300 |     |     |     |     |     |     |
| KRT2B        | >125| DRAM1 | <50  |     |     |     |     |     |     |
| NID1         | >35 | ESM1  | >200 |     |     |     |     |     |     |
| MMP1         | >375| TFFP  | <750 |     |     |     |     |     |     |
| PXDN         | >125| SIRPB1 | >1300 |     |     |     |     |     |     |
| HPGD         | <350|     |     |     |     |     |     |     |     |
| CXCL8        | >250|     |     |     |     |     |     |     |     |
| CXCL6        | <100|     |     |     |     |     |     |     |     |
| SLAMF6       | <700|     |     |     |     |     |     |     |     |
is known regarding the biological differences occurring with this disease transition. In contrast, the gene profiling analysis identified an array of genes with levels that were expressed uniquely at 3 months (late progression) and were able to discriminate this disease phase. These included immune pathways and, of particular note was the large array of gene expression changes related to formation and recombination events for antibody molecules. Moreover, some genes that were increased at 1 month continued to increase to an even greater extent at 3 months, while other members of this late progressing panel were elevated only at this phase of disease. These patterns enabled the identification of a set of 67 genes that could be assembled into 4 clusters and used to classify health and disease phases. Creating thresholds for individual gene expression, the 4 clusters effectively classified the specimens from healthy sites with > 80% accuracy and delineated the initiation and late progression samples at 72% and 94% accuracy, respectively.

Finally, the data provided insight into fundamental biologic differences between gingival tissues of periodontal health and clinically normal gingiva at sites where the lesion has resolved. In this regard, there is actually quite limited data regarding gene expression profiles in human tissues following non-surgical therapy. Beikler et al.45 examined a limited subset of gene encompassing inflammatory responses, as well as epithelial, connective, and endothelial tissues cellular responses. As such, our model in which we mitigate local inciting factors similar to scaling and root planing in humans provides some insights into addressing differences in healthy tissues compared to tissues at sites of resolved lesions. As might be expected, there was a limited number of genes

| Gene set # | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | Total (%) |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----------|
| Health   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 83.3      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 0         |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 0         |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 11.1      |
| Initiation|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 66.7      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 72.2      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 38.9      |
| Early    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 0         |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 22.2      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 61.1      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 72.2      |
| Late     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 0         |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 0         |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 44.4      |
|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 94.4      |
| Gene set # | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | Total (%) |
| Health   | IA  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 83.3      |
|          | IB  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 16.7      |
| Resolution| IA |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 27.8      |
|          | IB  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 77.8      |

Figure 6. Map of response profiles for gene clusters for the 18 samples obtained at each of the timepoints. Red denotes sample demonstrated: Cluster I—> 13 genes; Cluster II—> 9 genes; Cluster III—> 7 genes; Cluster IV—> 7 genes with signal greater or less than the threshold cutoff normalized signal (Tc, Table 3). Green denotes sample exhibited fewer genes above or below the Tc. Similar depiction of the distribution of responses to Cluster I genes subgrouped into IA and IB. Red denotes IA—> 2 genes and IB—> 3 genes above/below the Tc (see Table 3). Total % denotes proportion of the samples that were positive in the gene expression cluster.
with expression differences between healthy and resolved gingival tissues representing epithelial biology and inflammatory responses. However, using additional threshold levels for expression of Cluster I genes 75–80% of the healthy versus resolved specimens were categorized accurately. Thus, the gingival tissues do not appear to return to complete biologic health within 60 days of clinical disease resolution. This might suggest that previously diseased sites that have been treated and resolved may appear clinically normal; however, they could remain biologically programmed for a heightened risk of disease related to a subsequent noxious challenge. Similarly a recent clinical study reported that even in well-maintained patients the oral microbiome seems more pathogenic than in healthy control sites without previous history of periodontitis. This finding also supports a new concept related to the recent classification scheme for periodontitis and reinforces the concept that a patient with periodontal disease experience will be always a patient with enhanced periodontal disease risk even after reaching clinically healthy conditions.

While this report focused on characterizing the gingival transcriptome in this model of health, disease, and resolution, it cannot be ignored that there also occur parallel changes in the oral microbiome with increases in pathobionts and a resulting dysbiosis that reflects and/or drives the tissue destructive features of periodontitis. Importantly, there exists a reasonable linkage between reported microbiome changes and the features of gene expression changes that were identified. P. gingivalis hallmarks these changes by impacting apoptosis and autophagy processes allowing it to invade, survive, and disrupt the normal lifecycle of epithelial cells. Additionally, other reports have documented dysregulated inflammatory, protective, and cellular integrity for an array of genes induced by numerous oral bacteria. Related to the array of genes that were altered with disease initiation and progression, a number of proposed oral pathogens also have the capacity to translocate to deeper tissues and create intraepithelial/mucosal microbial communities. This process would trigger an enhanced

| Cluster | Protein | Fluid | Biologic linkage |
|---------|---------|-------|------------------|
| I       | ALOX12B | Serum/plasma | Diabetes         |
| I       | CRNN    | Serum/plasma | Epithelial-induced stress protein |
| I       | CSF3R   | Serum/plasma | Cancer related gene |
| I       | CXCL6   | Serum/plasma/urine/saliva | Antibacterial/neutrophil |
| I       | CXCL8 (IL-8) | Serum/plasma/saliva | Pancreatic cancer; breast cancer |
| I       | ESM1    | Serum/saliva | (Endocan) CVD, PCOS |
| I       | HPGD    | Serum/plasma/saliva | Cancer |
| I       | MMP1    | Serum/plasma/saliva | CVD; arthritis |
| I       | NID1    | Plasma/saliva | Cancer |
| I       | PXDN    | Serum/plasma/saliva | Fibrosis |
| I       | TFPI    | Serum/plasma | Coagulation |
| I       | TNFRSF19| Serum/plasma | Cancer |
| I       | SERPINE2| Serum | Cancer |
| II      | TLR4    | Serum/plasma/saliva | Arthritis, autoimmunity |
| II      | ADAM12  | Serum/plasma | Fibrosis; lung disease |
| II      | KRT1    | Serum/plasma | Cancer |
| II      | MIR233  | Serum/plasma/saliva | Cancer; CVD |
| II      | MUC4    | Serum/cyst fluid/saliva | Cancer |
| II      | NOX4    | Serum/plasma | Inflammation |
| II      | PLAT    | Serum/plasma/saliva | CVD |
| II      | TEK     | Serum/plasma | Cancer, autoimmune |
| II      | HAS2    | Serum/plasma/saliva | Inflammation; arthritis |
| III     | CD36    | Serum/plasma | Foam cell formation (CVD) |
| III     | KYNU    | Serum/plasma | Psoriasis |
| III     | GREM1   | Serum | Inflammation |
| III     | FPR3    | Serum | COPD |
| IV      | SERPINE1| Serum/plasma/saliva | CVD (PAI-1) |
| IV      | CEACAM8 | Serum/plasma/saliva | Arthritis |
| IV      | HGF     | Serum/plasma/saliva | Liver disease; cancer |
| IV      | NID2    | Serum/plasma/saliva | Cancer |
| IV      | SEL1    | Plasma | Alzheimer's; schizophrenia |
| IV      | SFSP4   | Serum/plasma | Diabetes |
| IV      | THBS1   | Serum/saliva | Obesity; pregnancy |
| IV      | TREM1   | Serum/saliva | Inflammatory bowel disease |

Table 5. Targeted biomarkers for periodontal lesion phases reported as diagnostic biomarkers for various inflammatory and non-inflammatory diseases.
inflammatory cell infiltrate and resulting microvascularization as a feature of the inflammatory response in disease\textsuperscript{25}. As such, the dysbiotic microbiome, related to an increased burden of individual pathogenic species, undermines the normal homeostatic mechanisms of the various gingival cells, with genes in the phase arrays from this study consistent with these microbial-induced changes\textsuperscript{22,23}. This model provided us the capacity to develop algorithms of gene expression that enabled phasing disease and distinguish between resolved and uninvolved healthy sites. Based upon existing data from cross-sectional human gingival transcriptomes\textsuperscript{34–37}, we can test these gene panels with the human data to potentially enhance the homogeneity of the human specimens for disease phases and resolution and identify with more precision biomarkers that may be useful in management of the human disease. However, utility of this specific gene expression knowledge would be limited for clinical care in humans since routine sampling of gingival tissues for targeted gene expression would not be feasible. Nevertheless, many of these genes would be predicted to result in secreted translated biomolecules that would be expected to be present in the gingival crevicular fluid and could even be detected in saliva to potentially discriminate health, disease phases, and resolved lesions. Importantly, as shown in Table 5 many of these biomolecules have already been evaluated and associate with many chronic inflammatory conditions. Based upon this unbiased approach to identification of potential biomarkers, panels of a finite number of gene products could be evaluated in humans to enable a better understanding of molecular mechanisms and development of targeted therapies with more precision.

**Methods**

**Animal model of periodontitis.** Rhesus monkeys (Macaca mulatta) (n = 18; 10 females and 8 males) aged 12–23 years housed at the Caribbean Primate Research Center at Sabana Seca, Puerto Rico\textsuperscript{58–60}. The nonhuman primates were typically fed a 20% protein, 5% fat, and 10% fiber commercial monkey diet (diet 8773, Teklad NIB primate diet modified: Harlan Teklad, Madison, WI). The diet was supplemented with fruits and vegetables, and water was provided ad libitum in an enclosed corral setting. All experimental protocols were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Puerto Rico and University of Kentucky. The methods were carried out in accordance with all relevant regulations for the use of nonhuman primates following ARRIVE guidelines. Anesthetized animals were examined by a single investigator using a Maryland probe on the facial aspect of the teeth, 2 proximal sites per tooth (mesio- and disto-buccal), excluding the canines and 3rd molars. The clinical examination included probing pocket depth (PD), and bleeding on probing (BOP; 0–5 scale)\textsuperscript{16}. Periodontal health was defined by mean Pocket Depth (PD) ≤ 3.0 mm and mean Bleeding on Probing (BOP) ≤ 1 (0–5 scale) in a full mouth examination excluding 3rd molars and canines\textsuperscript{61}. Determination of periodontal disease at the sampled site was documented by assessment of the presence of BOP and probing pocket depth of > 4 mm as we have described previously.

Ligature-induced periodontitis was induced in each of the animals at 1st premolar and 1st and 2nd molars in all 4 quadrants following a baseline sampling of gingival tissue from a healthy site. Further, clinical evaluation for ligated sites was obtained and a buccal gingival papilla from each animal was taken using a standard gingivectomy technique at 2 weeks (initiation of disease), and 1 month and 3 months (progression of disease). Then, ligatures were removed after sampling at 3 months and samples taken 2 months later (resolution)\textsuperscript{28,62,63}. Since the removal of the ligature eliminates the local noxious mechanical challenge and decreases the microbial burden accumulating at the tooth, this process is similar to nonsurgical periodontal therapy in humans. Previously published histological studies have documented the significant increase in inflammatory cell infiltrate in the ligated tissues consistent with the clinical features of inflammation and increasing probing pocket depth\textsuperscript{20,65}.

**Gingival tissue sample collection and mRNA analysis.** Gingival tissue samples of healthy of disease sites were surgically collected as we have described previously providing buccal gingival samples from either healthy or periodontitis-affected tissue from the premolar/molar maxillary region of each animal using a standard gingivectomy technique\textsuperscript{58,66,67}. Samples were maintained frozen at − 80 °C in RNA later solution until RNA preparation for microarray analysis. Total RNA was isolated from tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA). After cleaning with Qiagen RNaseasy mini kit (Qiagen, Valencia, CA, USA), all microarray RNA expression analyses were done at the University of Kentucky Microarray facility. Tissue RNA samples were submitted to the UK Microarray Core Facility and RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Reverse transcription of equal amounts of RNA from each sample was performed, followed by hybridization to the GeneChip Rhesus Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) similar to methods we have described previously\textsuperscript{59,67,68}. We have also previously published multiple reports examining an array of biologic pathways and included validation of numerous genes between the microarray and qPCR results\textsuperscript{64,65,68–71}. A summary of these results is displayed in Supplemental Fig. S2 that demonstrates, as we have noted previously, a significant relationship between the microarray and qPCR analyses regarding directional changes, albeit the qPCR tended to provide a somewhat broader range in the differential expression changes.

**Data analysis.** The expression intensities for genes across the 18 samples were estimated using the Robust Multi-array Average (RMA) algorithm with probe-level quintile normalization, as implemented in the Partek Genomics Suite software version 6.6 (Partek, St. Louis, MO). The different groups were initially compared using one-way ANOVA. For genes that had significant mean differences, two sample t-tests were used to investigate differences. The data has been uploaded into the ArrayExpress data base (www.ebi.ac.uk) under accession number: E-MTAB-1977. A number of Affymetrix probes with unique expression profiles in the samples had not been annotated. For these, we used the Ensembl ID (EMBL-EBI) to extract out the nucleotide base sequence for the probe from the Affymetrix Exon/Locus (http://www.affymetrix.com/index/affx#1_2) website. This
sequence was then searched in Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and the highest percent identity for *M. mulatta* selected.

Normalized expression profiles of genes that were differentially expressed at least across one of the time points Baseline, 2 weeks, 1 Month, 3 Months, and 5 Months with the remaining time points as background were used as input to Principal component analysis (PCA) 

The first and second dominant eigen values explained ~62% of the variance in the given data and two-dimensional projection of the gene expression profile revealed inherent clustering of the time points.

Received: 29 January 2021; Accepted: 9 April 2021
Published online: 29 April 2021

**References**

1. Lamont, R. J., Koo, H. & Hajishengallis, G. The oral microbiota: Dynamic communities and host interactions. *Nat. Rev. Microbiol.* **16**, 745–759. https://doi.org/10.1038/s41579-018-0089-x (2018).

2. Ebersole, J. L. *et al.* Age and periodontal health: Immunological view. *Carr. Oral Health Rep.* **5**, 229–241 (2018).

3. Ebersole, J. L. *et al.* The periodontal war: Microbes and immunity. *Periodontol.* **75**, 52–115. https://doi.org/10.1111/prd.12222 (2017).

4. Chapple, I. L. C. *et al.* Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workshop 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J. Periodontol.* **89**(Suppl 1), S74–S84. https://doi.org/10.1002/JPER.17-0719 (2018).

5. Armitage, G. C. Learned and unlearned concepts in periodontal diagnostics: A 50-year perspective. *Periodontol.* **62**, 20–36. https://doi.org/10.1111/prd.12006 (2013).

6. Goodson, J. M. Diagnosis of periodontitis by physical measurement: Interpretation from episodic disease hypothesis. *J. Periodontol.* **63**(Suppl 4S), 373–382. https://doi.org/10.1902/jop.1992.63.4s.373 (1992).

7. Goodson, J. M. Clinical measurements of periodontitis. *J. Clin. Periodontol.* **13**, 446–460. https://doi.org/10.1111/j.1600-051x.1986.tb01489.x (1986).

8. Koch, G. G. & Paquette, D. W. Design principles and statistical considerations in periodontal clinical trials. *Ann. Periodontol./Am. Acad. Periodontol.* **2**, 42–63. https://doi.org/10.1902/annals.1997.2.1.42 (1997).

9. Graves, D. T., Kang, J., Andrianjkaja, O., Wada, K. & Rossa, C. Jr. Animal models to study host-bacteria interactions involved in periodontal disease. *Front. Oral Biol.* **15**, 117–132. https://doi.org/10.1590/00329675 (2012).

10. Oz, H. S. & Paleo, D. A. Animal models for periodontal disease. *J. Biomed. Biotechnol.* **2011**, 754857. https://doi.org/10.1155/2011/754857 (2011).

11. Abusleme, L. *et al.* Oral microbiome characterization in murine models. *Biol. Protec.* **7**, 15. https://doi.org/10.21769/BioProtoc.2655 (2017).

12. Hasturk, H., Goguet-Surmenian, E., Blackwood, A., Andry, C. & Kantarci, A. 1-Tetradecanol complex: Therapeutic actions in experimental periodontitis. *J. Periodontol.* **80**, 1103–1113. https://doi.org/10.1902/jop.2009.090002 (2009).

13. Hasturk, H. *et al.* Topical H2 antagonist prevents periodontitis in a rabbit model. *Infect. Immun* **74**, 2402–2414 (2006).

14. Ebersole, J. L. *et al.* Periodontal disease susceptible matrilines in the Cayo Santiago Macaca mulatta macaques. *J. Periodontal Res.* **54**, 134–142. https://doi.org/10.1111/j.1600-051x.2019.01916.x (2019).

15. Roth, G. S. *et al.* Aging in rhesus monkeys: Relevance to human health interventions. *Science* **305**, 1423–1426 (2004).

16. Ebersole, J. L., Steffen, M. J., Gonzalez-Martinez, J., & Novak, M. J. Effects of age and oral disease on systemic inflammatory and immune parameters in nonhuman primates. *Clin. Vaccine Immunol.* **15**, 1067–1075. https://doi.org/10.1128/CVI.00258-07 (2008).

17. Nibali, L. *et al.* Heritability of periodontitis: A systematic review of evidence from animal studies. *Arch. Oral Biol.* **109**, 104592. https://doi.org/10.1016/j.archoralbio.2019.104592 (2020).

18. de Coo, A., Quintela, I., Blanco, J., Diz, P. & Carracedo, A. Assessment of genotyping tools applied in genetic susceptibility studies of periodontal disease: A systematic review. *Arch. Oral Biol.* **92**, 38–50. https://doi.org/10.1016/j.arcbio.2018.04.012 (2018).

19. Munz, M. *et al.* A genome-wide association study identifies nucleotide variants at SIGLEC5 and DEFA1A3 as risk loci for periodontitis. *Hum. Mol. Genet.* **26**, 2577–2588. https://doi.org/10.1093/hmg/ddx151 (2017).

20. Eke, P. I. *et al.* Risk indicators for periodontitis in US adults: NHANES 2009 to 2012. *J. Periodontol.* **87**, 1174–1185. https://doi.org/10.1902/jop.2016.160013 (2016).

21. Eke, P. I. *et al.* Periodontitis prevalence in adults >/= 65 years of age, in the USA. *Periodontol. 2000* **72**, 76–95. https://doi.org/10.1111/prd.12145 (2015).

22. Eke, P. I. *et al.* Update on prevalence of periodontitis in Adults: NHANES 2009–2012. *J. Periodontol.* https://doi.org/10.1902/jop.2015.140520 (2015).

23. Lifshitz, F., Casavalle, P. L., Bordoni, N., Rodriguez, P. N. & Friedman, S. M. Oral health in children with obesity or diabetes mellitus. *Pediatr. Endocrinol. Rev.* **14**, 159–167. https://doi.org/10.17458/PER.2016.LCB.Orthalhealth (2016).

24. Song, H. J. Periodontal considerations for children. *Dent. Clin. North Am.* **57**, 13–37. https://doi.org/10.1016/j.dcl.2012.09.009 (2013).

25. Albandar, J. M. Epidemiology and risk factors of periodontal diseases. *Dent. Clin. North Am.* **49**(517–532), v–vi (2005).

26. Papapanou, P. N. Population studies of microbial ecology in periodontal health and disease. *Ann. Periodontol./Am. Acad. Periodontol.* **7**, 54–61 (2002).

27. Binstein, E., Ram, D., Ishdied, J., Naor, R. & Sela, M. N. Periodontal diseases, caries, and microbial composition of the subgingival plaque in children: A longitudinal study. *AIDSDC J. Dent. Child.* **69**, 133–137 (2002).

28. Madden, T. E. & Caton, J. G. Animal models for periodontal disease. *Methods Enzymol.* **235**, 106–119 (1994).

29. Freire, M. O. & Van Dyke, T. E. Natural resolution of inflammation. *Periodontol. 63*, 149–164. https://doi.org/10.1111/prd.12034 (2013).

30. Kantarci, A. & Van Dyke, T. E. Resolution of inflammation in periodontitis. *J. Periodontol.* **76**, 2168–2174 (2005).

31. Armitage, G. C. & Robertson, P. B. The biology, prevention, diagnosis and treatment of periodontal diseases: Scientific advances in the United States. *J. Am. Dent. Assoc.* **140**(Suppl 1), 365-435 (2009).

32. Ebersole, J. L., Singer, R. E., Steffensen, B., Filloon, T. & Kornman, K. S. Inflammatory mediators and immunoglobulins in GCF from healthy, gingivitis and periodontitis sites. *J. Periodontal Res.* **28**, 543–546 (1993).

33. Sadeghi, R., Sattari, M., Dehghan, F. & Akbari, S. Interleukin-17 and interleukin-23 levels in gingival crevicular fluid of patients with chronic and aggressive periodontitis. *Cent. Eur. J. Immunol.* **43**, 76–80. https://doi.org/10.5114/cej.2018.74876 (2018).

34. Bostanci, N. *et al.* Gingival exudate dynamics implicate inhibition of the alternative complement pathway in the protective action of the C3 inhibitor Cp40 in nonhuman primate periodontitis. *J. Proteome Res.* **17**, 3153–3175. https://doi.org/10.1021/acs.jproteome.8b00263 (2018).
75. Thullier, P., Huish, O., Pelat, T. & Martin, A. C. The humanness of macaque antibody sequences. J. Mol. Biol. 396, 1439–1450. https://doi.org/10.1016/j.jmb.2009.12.041 (2010).

Acknowledgements
We thank the University of Kentucky Microarray Core for initial analytic support. The work was supported by USPHS grants GM103538/RR020145 and RR03640 to the Caribbean Primate Research Center. Contributions to this work were JLE and OAG in the development and implementation of the protocol, sample collection, data analysis and interpretation, and preparation of the manuscript, SK for preparation of samples, and RN provided the data management, strategy for analysis, and revision of the manuscript. The authors have no conflict of interests with the contents of this report.

Author contributions
Contributions to this work were J.L.E. and O.A.G. in the development and implementation of the protocol, sample collection, data analysis and interpretation, and preparation of the manuscript, S.K. for preparation of samples, and R.N. provided the data management, strategy for analysis, and revision of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-88803-6.

Correspondence and requests for materials should be addressed to J.L.E.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021